Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome

Thrombosis and Haemostasis

Volumn 104, Issue 5, 2010, Pages 976-983

  Becker, Richard C ^a   Alexander, John H ^a   Newby, L Kristin ^a   Yang, Hongqiu ^a   Barrett, Yuchen ^b   Mohan, Puneet ^b   Wang, Jessie ^b   Harrington, Robert A ^a   Wallentin, Lars C ^c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

Author keywords

Acute coronary syndrome; Apixaban; Oral factor Xa antagonists

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; APIXABAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10A INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PLACEBO; PROTHROMBIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METHODOLOGY; MULTIVARIATE ANALYSIS; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD COAGULATION; CHI-SQUARE DISTRIBUTION; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XA; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; ODDS RATIO; PARTIAL THROMBOPLASTIN TIME; PEPTIDE FRAGMENTS; PLACEBO EFFECT; PROTHROMBIN; PYRAZOLES; PYRIDONES; TANDEM MASS SPECTROMETRY; THROMBIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 78149476902     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-04-0247     Document Type: Article

References (16)

1. Pinto DJ, et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2- oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H -pyrazolo[3,4-c]pyridine-3- carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007; 50: 5339-5356.
2. Wang L, et al. Sulfation of o-demethyl apixaban: enzyme identification and species comparison. Drug Metab Dispos 2009; 37: 802-808.
3. Raghavan N, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37: 74-81.
4. Zhang D, et al. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos 2009; 37: 1738-1748.
5. Cannon CP, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375: 283-293.
6. Buller H, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 1313-1318.
7. APPRAISE Steering Committee and Investigators, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119: 2877-2885.
8. Lassen MR, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-815.
9. Christersson C, et al. Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial. Eur Heart J 2007; 28: 692-698. (Pubitemid 46439238)
10. Becker RC, et al. Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease. Thromb Res 2006; 117: 439-446.
11. Mega JL, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374: 29-38.
12. Gibson CM, et al. Effect of Rivaroxaban on Markers of Coagulation in Patients With Acute Coronary Syndromes: An ATLAS ACS-TIMI 46 Substudy. Circulation 2009; 120 (Suppl 18): S1035-a- (Abstract 5020).
13. Ardissino D, et al. Thrombin activity and early outcome in unstable angina pectoris. Circulation 1996; 93: 1634-1639.
14. Empana JP, et al. Contribution of novel biomarkers to incident stable angina and acute coronary syndrome: the PRIME Study. Eur Heart J 2008; 29: 1966-1974.
15. Menown IB, et al. Prediction of Recurrent Events by D-Dimer and Inflammatory Markers in Patients with Normal Cardiac Troponin I (PREDICT) Study. Am Heart J 2003; 145: 986-992.
16. Eriksson BI, et al. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost 2008; 6: 457-463.